Presentation is loading. Please wait.

Presentation is loading. Please wait.

Jennifer A. Cowger, MD, Matthew A

Published bySilas Shaw Modified over 6 years ago

Similar presentations

Presentation on theme: "Jennifer A. Cowger, MD, Matthew A"— Presentation transcript:

1 Hemolysis: A harbinger of adverse outcome after left ventricular assist device implant 
Jennifer A. Cowger, MD, Matthew A. Romano, MD, Palak Shah, MD, MS, Neha Shah, MBBS, CCRP, Vivek Mehta, BS, Jonathan W. Haft, MD, Keith D. Aaronson, MD, MS, Francis D. Pagani, MD, PhD  The Journal of Heart and Lung Transplantation  Volume 33, Issue 1, Pages (January 2014) DOI: /j.healun Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

2 Figure 1 Frequency of hemolysis episodes. The percentage of patients in the study cohort experiencing any hemolysis episode based on biochemical parameters (sfHg > 40 mg/dL or LDH ≥ 600 IU/L), INTERMACS-defined hemolysis (sfHg > 40 mg/dL with signs/symptoms), LDH-defined hemolysis (LDH ≥ 600 IU/L), or dual-hemolysis (simultaneous sfHg > 40 mg/dL and LDH ≥ 600 IU/L). The Journal of Heart and Lung Transplantation  , 35-43DOI: ( /j.healun ) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

3 Figure 2 Time to onset of index hemolysis episode based on Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS; red) and lactate dehydrogenase (LDH; blue) criteria after ventricular assist device implant. The Journal of Heart and Lung Transplantation  , 35-43DOI: ( /j.healun ) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

4 Figure 3 Event-free survival after left ventricular assist device implant in patients with and without hemolysis. Kaplan-Meier survival free of death, device exchange for thrombosis, urgent United Network of Organ Sharing 1A transplant for device thrombosis, or peripheral embolism/stroke after device implant is shown in patients with and without Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-defined hemolysis (serum free hemoglobin > 40 mg/dL plus symptoms) and with and without lactate dehydrogenase (LDH)-defined hemolysis (LDH ≥ 600 IU/L). The Journal of Heart and Lung Transplantation  , 35-43DOI: ( /j.healun ) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

5 Figure 4 Event-free survival after hemolysis onset. Kaplan-Meier survival free of death, peripheral embolism, urgent United Network of Organ Sharing 1A transplant for device thrombosis, or device exchange for thrombosis is shown in patients with and without Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-defined hemolysis (serum free hemoglobin > 40 mg/dl plus symptoms) and in patients with and without lactate dehydrogenase (LDH)-defined hemolysis (LDH ≥ 600 IU/L). *Days represents days from onset of INTERMACS or LDH-defined hemolysis (LDH ≥600 IU/L) or from device implant (in non-hemolyzers) to an event. The Journal of Heart and Lung Transplantation  , 35-43DOI: ( /j.healun ) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

6 Figure 5 This graphic shows the median time-to-event onset after left ventricular assist device (LVAD) implant and the median time-to-event occurrence after onset of Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-defined (red) and lactate dehydrogenase (LDH)-defined (blue) hemolysis. XC, exchange. The Journal of Heart and Lung Transplantation  , 35-43DOI: ( /j.healun ) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

Download ppt "Jennifer A. Cowger, MD, Matthew A"

Similar presentations

Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.

Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.
Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.

Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.
Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,

Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,
Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,

Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,
Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I

Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I
Fenton H. McCarthy, MD, Dale Kobrin, BA, J. Eduardo Rame, MD, Peter W

Fenton H. McCarthy, MD, Dale Kobrin, BA, J. Eduardo Rame, MD, Peter W
Evan P. Kransdorf, MD, PhD, Michelle M. Kittleson, MD, PhD, Jignesh K

Evan P. Kransdorf, MD, PhD, Michelle M. Kittleson, MD, PhD, Jignesh K
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device  David Dobarro, MD, Marian Urban, MD, Karen.

Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device  David Dobarro, MD, Marian Urban, MD, Karen.
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
The Registry of the International Society for Heart and Lung Transplantation: Twenty- seventh official adult heart transplant report—2010  Josef Stehlik,

The Registry of the International Society for Heart and Lung Transplantation: Twenty- seventh official adult heart transplant report—2010  Josef Stehlik,
Symptom-to-Balloon Time is a Strong Predictor of Adverse Events Following Primary Percutaneous Coronary Intervention: Results From the Australian Capital.

Symptom-to-Balloon Time is a Strong Predictor of Adverse Events Following Primary Percutaneous Coronary Intervention: Results From the Australian Capital.
Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease:

Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease:
Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score 

Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score 
Adverse Events in Children Implanted With Ventricular Assist Devices in the US: Data From the Pediatric Interagency Registry for Mechanical Circulatory.

Adverse Events in Children Implanted With Ventricular Assist Devices in the US: Data From the Pediatric Interagency Registry for Mechanical Circulatory.
Outcomes in highly sensitized pediatric heart transplant patients using current management strategies  Alfred Asante-Korang, MD, Ernest K. Amankwah, PhD,

Outcomes in highly sensitized pediatric heart transplant patients using current management strategies  Alfred Asante-Korang, MD, Ernest K. Amankwah, PhD,
Severe Mitral Regurgitation at Time of Left Ventricular Assist Device Implantation - Comparison of Systematic Mitral Valve Repair vs Surgical Abstention 

Severe Mitral Regurgitation at Time of Left Ventricular Assist Device Implantation - Comparison of Systematic Mitral Valve Repair vs Surgical Abstention 
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Palliative Medicine and Preparedness Planning for Patients Receiving Left Ventricular Assist Device as Destination Therapy—Challenges to Measuring Impact.

Palliative Medicine and Preparedness Planning for Patients Receiving Left Ventricular Assist Device as Destination Therapy—Challenges to Measuring Impact.

Similar presentations

Ads by Google